TrialBlood2025

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.

Martha L Arellano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.